<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01050569</url>
  </required_header>
  <id_info>
    <org_study_id>237</org_study_id>
    <secondary_id>1R01DA025598</secondary_id>
    <nct_id>NCT01050569</nct_id>
  </id_info>
  <brief_title>Innovative Interventions for Smoking Cessation</brief_title>
  <official_title>Innovative Interventions for Smoking Cessation: Comparison of Very Low Nicotine Content Cigarettes Plus Nicotine Patch; Very Low Nicotine Content Cigarettes Alone or Nicotine Patch Alone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota - Clinical and Translational Science Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Minnesota - Clinical and Translational Science Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effect of a combination of the 21 mg nicotine
      patch and very low nicotine content (VLNC) cigarettes compared to 21 mg nicotine patch only
      and very low nicotine content cigarette only on abstinence, time to relapse and toxicant
      levels. The study will determine if adding nicotine replacement medication to the very low
      content cigarettes (VLNC) will augment treatment compared to nicotine patch only or to very
      low nicotine content cigarettes only.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate the effect of a combination of the 21 mg nicotine
      patch and very low nicotine content cigarette (VLNC) compared to the VLNC cigarette alone or
      21 mg nicotine patch alone on abstinence, time to relapse and toxicant levels.

      The following primary hypothesis will be tested:

      Abstinence rates will be highest and the time to relapse will be the longest in the VLNC
      cigarettes plus nicotine patch condition compared to nicotine patch or VLNC cigarettes alone.

      Other hypotheses include:

        1. Greater positive subjective responses to cigarettes will be observed with VLNC
           cigarettes plus patch vs. VLNC cigarette;

        2. Less drop-outs will be observed in the VLNC plus patch vs the other two conditions; and

        3. Less compensatory smoking will be observed in the VLNC plus patch condition compared to
           VLNC cigarette alone condition.

      Cigarette smokers will be randomized to:

        1. VLNC cigarettes (which provide sensory behavioral aspects of smoking but with limited
           nicotine) plus nicotine patch for 6 weeks;

        2. Nicotine patch for 6 weeks; or

        3. VLNC cigarettes alone.

      Outcome measures will include cessation assessed at the end of treatment as the primary
      endpoint and at 36 weeks post-treatment, time to lapse and relapse to usual brand cigarettes,
      and biomarkers of toxicant exposure. Predictors of abstinence and treatment response for each
      of the treatment conditions will be explored.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>End of Treatment Abstinence Rate</measure>
    <time_frame>12 week</time_frame>
    <description>Cotinine and carbon monoxide (CO) verified point prevalence abstinence</description>
  </primary_outcome>
  <primary_outcome>
    <measure>End of Follow-up Abstinence Rates</measure>
    <time_frame>36 weeks</time_frame>
    <description>CO- and cotinine-verified point prevalence abstinence</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Exposure to Tobacco Toxicants</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Lapse or Relapse to Tobacco Use</measure>
    <time_frame>26 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">235</enrollment>
  <condition>Tobacco Use Disorder</condition>
  <arm_group>
    <arm_group_label>VLNC Cigarette</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Very Low Nicotine Content Cigarette. Dosage: 0.05 mg to 0.09 mg nicotine yield cigarette; Frequency: Daily; Duration: 6 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nicotine Patch</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>21 mg nicotine patch. Dosage: 21 mg; Frequency: Daily; Duration: 6 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VLNC Cigarette plus Nicotine Patch</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Very Low Nicotine Content Cigarette plus 21 mg Nicotine Patch. Patch Dosage: 21 mg; Cigarette Dosasge: 0.05 to 0.09 mg nicotine yield; Frequency: Daily; Duration: 6 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotine Patch</intervention_name>
    <description>21 mg</description>
    <arm_group_label>Nicotine Patch</arm_group_label>
    <other_name>Nicoderm CQ</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>VLNC Cigarette</intervention_name>
    <description>Cigarette where the tobacco contains &lt;0.1 mg of nicotine yield.</description>
    <arm_group_label>VLNC Cigarette</arm_group_label>
    <other_name>Quest 3</other_name>
    <other_name>Xodus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>VLNC Cigarette Plus Nicotine Patch</intervention_name>
    <description>21 mg nicotine patch plus use of cigarette with tobacco containing &lt;0.1 mg nicotine yield.</description>
    <arm_group_label>VLNC Cigarette plus Nicotine Patch</arm_group_label>
    <other_name>Nicoderm CQ</other_name>
    <other_name>Quest 3</other_name>
    <other_name>Xodus</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  a) Smoking at least 10 cigarettes daily for the past year;

          -  b) In good physical health;

          -  c) No contraindications for medicinal nicotine; and

          -  d) Stable, good mental health.

        Exclusion Criteria:

          -  a) Subjects must not be using other tobacco or nicotine products.

          -  b) Female subjects cannot be pregnant or nursing and must be using appropriate birth
             control.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dorothy Hatsukami, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota - Clinical and Translational Science Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Duluth</city>
        <state>Minnesota</state>
        <zip>55812</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of MN's Tobacco Use Research Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55414</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Hatsukami DK, Hertsgaard LA, Vogel RI, Jensen JA, Murphy SE, Hecht SS, Carmella SG, al'Absi M, Joseph AM, Allen SS. Reduced nicotine content cigarettes and nicotine patch. Cancer Epidemiol Biomarkers Prev. 2013 Jun;22(6):1015-24. doi: 10.1158/1055-9965.EPI-12-1439. Epub 2013 Apr 19.</citation>
    <PMID>23603206</PMID>
  </results_reference>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 14, 2010</study_first_submitted>
  <study_first_submitted_qc>January 14, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2010</study_first_posted>
  <results_first_submitted>October 29, 2013</results_first_submitted>
  <results_first_submitted_qc>January 14, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 28, 2014</results_first_posted>
  <last_update_submitted>November 16, 2016</last_update_submitted>
  <last_update_submitted_qc>November 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Smoking Cessation</keyword>
  <keyword>Nicotine Free Cigarettes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tobacco Use Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Oct 2008 to September 2011 Location was at the University of Minnesota Twin Cities and Duluth, Minnesota</recruitment_details>
      <pre_assignment_details>After signing consent and before randomization to groups, 44 were lost to follow-up, 17 were ineligible, 10 were no longer interested, 10 were family members of enrollees.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>VLNC Cigarette</title>
          <description>Very Low Nicotine Content Cigarette: Cigarette where the tobacco contains &lt;0.1 mg of nicotine yield. Participants were asked to smoke experimental cigarettes in an ad lib basis. Product was used for 6 weeks.</description>
        </group>
        <group group_id="P2">
          <title>VLNC Cigarette Plus Nicotine Patch</title>
          <description>Very Low Content Cigarette Plus Nicotine Patch: 21 mg nicotine patch plus use of cigarette with tobacco containing &lt;0.1 mg nicotine yield. Nicotine patch was administered on a daily basis. Participants were asked to use experimental cigarettes on an ad lib basis. Products were used for 6 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Nicotine Patch</title>
          <description>Nicotine Patch: 21 mg. Nicotine patch was administered on a daily basis for a period of 6 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="79"/>
                <participants group_id="P2" count="76"/>
                <participants group_id="P3" count="80"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="52"/>
                <participants group_id="P3" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="33"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>VLNC Cigarette</title>
          <description>Very Low Nicotine Content Cigarettes : Cigarette where the tobacco contains &lt;0.1 mg of nicotine yield.</description>
        </group>
        <group group_id="B2">
          <title>VLNC Cigarette Plus Nicotine Patch</title>
          <description>VLNC Cigarette Plus Nicotine Patch: 21 mg nicotine patch plus use of cigarette with tobacco containing &lt;0.1 mg nicotine yield.</description>
        </group>
        <group group_id="B3">
          <title>Nicotine Patch</title>
          <description>21 mg nicotine patch</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="79"/>
            <count group_id="B2" value="76"/>
            <count group_id="B3" value="80"/>
            <count group_id="B4" value="235"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                    <measurement group_id="B2" value="74"/>
                    <measurement group_id="B3" value="76"/>
                    <measurement group_id="B4" value="225"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.5" spread="12.2"/>
                    <measurement group_id="B2" value="47.0" spread="11.9"/>
                    <measurement group_id="B3" value="47.3" spread="11.0"/>
                    <measurement group_id="B4" value="47.0" spread="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="46"/>
                    <measurement group_id="B4" value="136"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79"/>
                    <measurement group_id="B2" value="76"/>
                    <measurement group_id="B3" value="80"/>
                    <measurement group_id="B4" value="235"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>End of Treatment Abstinence Rate</title>
        <description>Cotinine and carbon monoxide (CO) verified point prevalence abstinence</description>
        <time_frame>12 week</time_frame>
        <group_list>
          <group group_id="O1">
            <title>VLNC Cigarette</title>
            <description>VLNC Cigarettes: Cigarette where the tobacco contains &lt;0.1 mg nicotine yield.</description>
          </group>
          <group group_id="O2">
            <title>VLNC Cigarette Plus Nicotine Patch</title>
            <description>Very Low Nicotine Cigarette Plus Nicotine Patch: 21 mg nicotine patch plus use of cigarette with tobacco containing &lt;0.1 mg nicotine yield.</description>
          </group>
          <group group_id="O3">
            <title>Nicotine Patch</title>
            <description>21 mg nicotine patch</description>
          </group>
        </group_list>
        <measure>
          <title>End of Treatment Abstinence Rate</title>
          <description>Cotinine and carbon monoxide (CO) verified point prevalence abstinence</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>End of Follow-up Abstinence Rates</title>
        <description>CO- and cotinine-verified point prevalence abstinence</description>
        <time_frame>36 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>VLNC Cigarette</title>
            <description>Very Low Nicotine Content Cigarettes: Cigarette where the tobacco contains &lt;0.1 mg of nicotine yield.</description>
          </group>
          <group group_id="O2">
            <title>VLNC Cigarette Plus Nicotine Patch</title>
            <description>Very Low Nicotine Content Cigarette Plus Nicotine Patch: 21 mg nicotine patch plus use of cigarette with tobacco containing &lt;0.1 mg nicotine yield.</description>
          </group>
          <group group_id="O3">
            <title>Nicotine Patch</title>
            <description>21 mg nicotine patch</description>
          </group>
        </group_list>
        <measure>
          <title>End of Follow-up Abstinence Rates</title>
          <description>CO- and cotinine-verified point prevalence abstinence</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Exposure to Tobacco Toxicants</title>
        <time_frame>6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>VLNC Cigarette</title>
            <description>Very Low Nicotine Content Cigarettes: Cigarette where the tobacco contains &lt;0.1 mg of nicotine yield.</description>
          </group>
          <group group_id="O2">
            <title>VLNC Cigarette Plus Nicotine Patch</title>
            <description>Very Low Nicotine Content Cigarette Plus Nicotine Patch : 21 mg nicotine patch plus use of cigarette with tobacco containing &lt;0.1 mg nicotine yield.</description>
          </group>
          <group group_id="O3">
            <title>Nicotine Patch</title>
            <description>21 mg nicotine patch</description>
          </group>
        </group_list>
        <measure>
          <title>Exposure to Tobacco Toxicants</title>
          <units>pmol/mg creatinine</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Urinary 4-(methylnitrosamino)-1-(3-pyridyl)-1-buta</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.40" lower_limit="0.29" upper_limit="0.55"/>
                    <measurement group_id="O2" value="0.26" lower_limit="0.19" upper_limit="0.36"/>
                    <measurement group_id="O3" value="0.25" lower_limit="0.18" upper_limit="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Nicotine Exposure (TNE)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.89" lower_limit="4.26" upper_limit="11.02"/>
                    <measurement group_id="O2" value="27.39" lower_limit="17.29" upper_limit="43.38"/>
                    <measurement group_id="O3" value="23.10" lower_limit="14.59" upper_limit="36.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cotinine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.03" lower_limit="1.20" upper_limit="3.45"/>
                    <measurement group_id="O2" value="7.65" lower_limit="4.59" upper_limit="12.76"/>
                    <measurement group_id="O3" value="5.50" lower_limit="3.31" upper_limit="9.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Lapse or Relapse to Tobacco Use</title>
        <time_frame>26 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>VLNC Cigarette</title>
            <description>Very Low Nicotine Content Cigarettes: Cigarette where the tobacco contains &lt;0.1 mg of nicotine yield.</description>
          </group>
          <group group_id="O2">
            <title>VLNC Plus Nicotine Patch</title>
            <description>Very Low Nicotine Content Cigarette Plus Nicotine Patch: 21 mg nicotine patch plus use of cigarette with tobacco containing &lt;0.1 mg nicotine yield.</description>
          </group>
          <group group_id="O3">
            <title>Nicotine Patch</title>
            <description>21 mg nicotine patch</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Lapse or Relapse to Tobacco Use</title>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" lower_limit="1.7" upper_limit="5.9"/>
                    <measurement group_id="O2" value="7.1" lower_limit="6.7" upper_limit="7.7"/>
                    <measurement group_id="O3" value="2.1" lower_limit="1.6" upper_limit="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>VLNC Cigarette</title>
          <description>Very Low Nicotine Content Cigarettes : Cigarette where the tobacco contains &lt;0.1 mg of nicotine yield.</description>
        </group>
        <group group_id="E2">
          <title>VLNC Cigarette Plus Nicotine Patch</title>
          <description>VLNC Cigarette Plus Nicotine Patch: 21 mg nicotine patch plus use of cigarette with tobacco containing &lt;0.1 mg nicotine yield.</description>
        </group>
        <group group_id="E3">
          <title>Nicotine Patch</title>
          <description>21 mg nicotine patch</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="54" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="76"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="79"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="76"/>
                <counts group_id="E3" events="13" subjects_affected="13" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="14" subjects_affected="9" subjects_at_risk="79"/>
                <counts group_id="E2" events="18" subjects_affected="14" subjects_at_risk="76"/>
                <counts group_id="E3" events="18" subjects_affected="14" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Stomach Ache</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="76"/>
                <counts group_id="E3" events="13" subjects_affected="9" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="15" subjects_affected="11" subjects_at_risk="79"/>
                <counts group_id="E2" events="20" subjects_affected="10" subjects_at_risk="76"/>
                <counts group_id="E3" events="14" subjects_affected="7" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="76"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" events="42" subjects_affected="26" subjects_at_risk="79"/>
                <counts group_id="E2" events="55" subjects_affected="25" subjects_at_risk="76"/>
                <counts group_id="E3" events="26" subjects_affected="14" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Headaches</sub_title>
                <counts group_id="E1" events="26" subjects_affected="21" subjects_at_risk="79"/>
                <counts group_id="E2" events="25" subjects_affected="21" subjects_at_risk="76"/>
                <counts group_id="E3" events="29" subjects_affected="19" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Lightheadedness</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="79"/>
                <counts group_id="E2" events="12" subjects_affected="10" subjects_at_risk="76"/>
                <counts group_id="E3" events="12" subjects_affected="10" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Shakiness</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="79"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="76"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Belching</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="79"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="76"/>
                <counts group_id="E3" events="10" subjects_affected="8" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Sore Throat</sub_title>
                <counts group_id="E1" events="26" subjects_affected="14" subjects_at_risk="79"/>
                <counts group_id="E2" events="14" subjects_affected="11" subjects_at_risk="76"/>
                <counts group_id="E3" events="9" subjects_affected="5" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Sleep Disturbance</sub_title>
                <counts group_id="E1" events="28" subjects_affected="19" subjects_at_risk="79"/>
                <counts group_id="E2" events="100" subjects_affected="38" subjects_at_risk="76"/>
                <counts group_id="E3" events="90" subjects_affected="43" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle Aches</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="79"/>
                <counts group_id="E2" events="29" subjects_affected="8" subjects_at_risk="76"/>
                <counts group_id="E3" events="20" subjects_affected="15" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="15" subjects_affected="13" subjects_at_risk="79"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="76"/>
                <counts group_id="E3" events="15" subjects_affected="13" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Small sample size.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dorothy Hatsukami</name_or_title>
      <organization>University of Minnesota</organization>
      <phone>612 626-2121</phone>
      <email>hatsu001@umn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

